首頁 > 市場調查報告書 > 製藥

非專利藥糖尿病生物製劑生技仿製藥

胰島素市場規模、佔有率和成長分析（按產品類型、給藥裝置、類型、應用、分銷管道和地區分類）：產業預測（2026-2033 年）

市場調查報告書

商品編碼

1898001

胰島素市場規模、佔有率和成長分析（按產品類型、給藥裝置、類型、應用、分銷管道和地區分類）：產業預測（2026-2033 年）

Insulin Market Size, Share, and Growth Analysis, By Product Type (Rapid-Acting Insulin, Long-Acting Insulin,), By Delivery Device (Pens, Infusion Pumps), By Type, By Application, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月22日 | 出版商:

SkyQuest | 英文 192 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，胰島素市場規模將達到 213.1 億美元，到 2025 年將達到 216.3 億美元，到 2033 年將達到 244.1 億美元，在預測期（2026-2033 年）內，複合年成長率為 1.52%。

受糖尿病盛行率上升和藥物研發取得重大進展的推動，胰島素市場經歷了顯著成長。然而，來自GLP-1受體促效劑和其他第二型糖尿病治療藥物的競爭可能會阻礙這種擴張。該行業仍處於寡占狀態，諾和諾德、賽諾菲和禮來等主要企業佔據了相當大的市場佔有率。糖尿病是全球成長最快的慢性疾病之一，目前影響著超過5億成年人，這推動了對有效治療方法的需求。生產流程的創新正在推動市場動態，例如PhiAspi吸收率的提高以及目前唯一的吸入式胰島素Afrezza（無需注射）。此外，Oramed的口服胰島素膠囊等前景廣闊的研發成果可望徹底改變糖尿病的治療方式。

胰島素市場促進因素

全球糖尿病發生率的不斷上升是胰島素市場的主要促進因素。久坐不動的生活方式、不良的飲食習慣以及日益嚴重的肥胖問題，都顯著加劇了第1型和第2型糖尿病病例的增加。因此，人們對傳統和創新胰島素療法的需求日益成長，以幫助控制血糖值。這一趨勢在亞洲和非洲的都市區尤其明顯，當地生活方式和飲食習慣的改變進一步加速了對胰島素產品的需求。不斷成長的患者群體推動了市場的擴張，也凸顯了有效糖尿病管理解決方案的緊迫性。

胰島素市場限制因素

胰島素市場面臨的一大挑戰是胰島素治療費用高昂，這構成了一大障礙，尤其是在醫療資源匱乏的地區。創新長效胰島素類似物的價格可能令人望而卻步，限制了低收入患者的用藥。在醫療保險體系薄弱或缺乏的開發中國家，這種經濟負擔尤其突出，嚴重阻礙了患者獲得必要的糖尿病治療。這種情況凸顯了迫切需要更經濟實惠的解決方案，以確保所有患者，無論其經濟狀況或地理位置如何，都能獲得所需的胰島素並有效控制糖尿病。

胰島素市場趨勢

隨著傳統胰島素專利到期，胰島素市場正經歷著向生物相似藥的顯著轉變。這項轉變的驅動力在於人們日益認知到生物相似藥的成本效益，它們以更低的價格提供與傳統胰島素相當的治療效果。監管機構正發揮關鍵作用，他們加強了這些替代藥物的核准流程，有助於營造競爭環境，最終可能降低整體醫療成本。因此，患者，尤其是在胰島素價格歷來較高的地區，將更容易獲得糖尿病管理方案，這將進一步推動市場對生物相似胰島素的需求，並改變現有的治療模式。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭格局

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市集活動
主要企業市佔率（2025 年）

主要企業簡介

Eli Lilly and Company
Sanofi
Novo Nordisk A/S
Biocon
Boehringer Ingelheim International GmbH
Tonghua Dongbao Pharmaceutical Co. Ltd.
Wockhardt
Julphar
Novo Nordisk
Merck & Co., Inc.
Pfizer Inc.
AstraZeneca
Johnson & Johnson
Biocon Ltd.
Ypsomed AG
Gan & Lee Pharmaceuticals
Bioton SA
Adocia
Torrent Pharmaceuticals Ltd.
Ipsen
Dongbao Enterprise Group Co., Ltd.

簡介目錄

Product Code: SQMIG35A2943

Insulin Market size was valued at USD 21.31 Billion in 2024 and is poised to grow from USD 21.63 Billion in 2025 to USD 24.41 Billion by 2033, growing at a CAGR of 1.52% during the forecast period (2026-2033).

The insulin market is experiencing notable growth driven by the rising prevalence of diabetes and significant advancements in drug development. However, competition from GLP-1 receptor agonists and other medications for type 2 diabetes may hinder this expansion. This sector remains largely oligopolistic, with major players like Novo Nordisk, Sanofi, and Eli Lilly commanding substantial market shares. As one of the most rapidly increasing chronic health concerns globally, diabetes now affects over half a billion adults, pushing demand for effective treatments. Innovations in manufacturing processes are propelling market dynamics, exemplified by products like Fiasp, which enhances absorption, and Afrezza, the sole inhalable insulin option that negates the need for needles. Additionally, promising developments such as Oramed's oral insulin capsules are on the horizon, potentially reshaping the treatment landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Insulin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Insulin Market Segments Analysis

Global Insulin Market is segmented by Product Type, Delivery Device, Type, Application, Distribution Channel, and Region. Based on Product Type, the market is segmented into Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin, Biosimilar, Others. Based on Delivery Devices, the market is segmented into Pens, Infusion Pumps, Syringes, and Others. Based on Type, the market is segmented into Human Insulin, Insulin Analog. Based on Application, the market is segmented into Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus. Based on Distribution Channel, the market is segmented into Hospitals, Retail Pharmacies, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Insulin Market

The insulin market is primarily influenced by the growing incidence of diabetes worldwide. Factors such as sedentary lifestyles, poor dietary habits, and escalating obesity rates are significant contributors to the rise in both type 1 and type 2 diabetes cases. As a consequence, there is a heightened demand for insulin therapies, both traditional and innovative, to help manage blood glucose levels. This trend is particularly noticeable in urban regions of Asia and Africa, where shifts in lifestyle and dietary patterns further propel the need for insulin products. This increasing patient population underscores the market's expansion, highlighting the urgent need for effective diabetes management solutions.

Restraints in the Insulin Market

A significant challenge in the insulin market is the elevated cost of insulin therapy, which poses a barrier, particularly in regions with limited healthcare access. The price of innovative, long-acting insulin analogs can be prohibitively expensive, restricting access for low-income patients. These financial burdens are especially pronounced in developing nations, where healthcare reimbursement systems may be insufficient or entirely absent, leading to significant obstacles in obtaining essential diabetes treatment. This situation highlights the urgent need for more affordable solutions to ensure that all patients, regardless of their financial status or geographic location, can access the insulin they require for effective diabetes management.

Market Trends of the Insulin Market

The insulin market is witnessing a notable trend towards biosimilar insulin products as patents for traditional insulins expire. This transition is driven by growing recognition of the cost-effectiveness of biosimilars, which offer similar therapeutic benefits at reduced prices. Regulatory agencies are playing a pivotal role by enhancing the approval processes for these alternatives, fostering a more competitive landscape that can potentially lower overall healthcare expenses. As a result, patients, especially in regions with previously high insulin costs, may experience improved access to diabetes management options, further fueling the market demand for biosimilar insulins and transforming treatment paradigms.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Patent Analysis
Regulatory Landscape
PESTEL Analysis
Pipeline Analysis
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition
Customer & Buying Criteria Analysis

Insulin Market by Product Type

Market Overview
Rapid-Acting Insulin
- Insulin Lispro
- Insulin Lispro
- Insulin Glulisine
- Technosphere insulin
Long-Acting Insulin
- Insulin Detemir
- Insulin Glargine
- Insulin Glargine-yfgn
- Insulin Degludec
Combination Insulin
- NPH/Regular
- Protamine/Lispro
- Protamine/Aspart
Biosimilar
Others

Insulin Market by Delivery Device

Market Overview
Pens
Infusion Pumps
Syringes
Others

Insulin Market by Type

Market Overview
Human Insulin
Insulin Analog

Insulin Market by Application

Market Overview
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus

Insulin Market by Distribution Channel

Market Overview
Hospitals
Retail Pharmacies
Others

Insulin Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocon
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tonghua Dongbao Pharmaceutical Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Wockhardt
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Julphar
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocon Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ypsomed AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gan & Lee Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioton S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adocia
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Torrent Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dongbao Enterprise Group Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments